文献速递糖尿病

住院时使用西格列汀与2型糖尿病合并COVID-19患者死亡率降低相关:多中心病例对照回顾性观察研究

Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study.
PubMed 文献 · Diabetes Care · 2020-09-29

该多中心病例对照回顾性观察研究纳入338例因COVID-19住院的2型糖尿病患者,住院时在标准治疗基础上加用西格列汀者169例,按年龄和性别1:1匹配的未治疗对照169例。西格列汀组死亡率18%低于对照组37%(HR 0.44,95%CI 0.29-0.66,P=0.0001),临床改善率和出院人数亦更高。

要点

  • 住院时加用西格列汀与死亡率降低相关(18% vs 37%,HR 0.44)。
  • 西格列汀组临床改善率60% vs 38%,出院人数120 vs 89。
  • 结论需在正在进行的随机安慰剂对照试验中确认。

核心结论

  • 在因COVID-19住院的2型糖尿病患者中,住院时使用西格列汀与标准治疗相比,与死亡率降低和临床结局改善相关。

研究设计与样本

  • 多中心、病例对照、回顾性、观察性研究,纳入意大利北部医院338例连续住院的2型糖尿病合并COVID-19患者。
  • 西格列汀组169例,在每个中心按1:1比例招募年龄和性别匹配的未治疗对照169例。
  • 所有患者均有肺炎,在呼吸环境空气或接受氧支持时氧饱和度<95%。

主要发现

  • 西格列汀组死亡18%,对照组死亡37%,风险比0.44(95%CI 0.29-0.66),P=0.0001。
  • 西格列汀组临床改善(七分类改良序贯量表至少增加两分)60%,对照组38%,P=0.0001。
  • 西格列汀组出院120例,对照组出院89例,P=0.0008。

临床怎么用

  • 对于因COVID-19住院的2型糖尿病患者,住院时在标准治疗基础上加用西格列汀可能改善预后,但需等待随机对照试验确认。

局限性

  • 为回顾性、观察性、病例对照设计,存在残余混杂可能。
  • 作者指出西格列汀的效果需在正在进行的随机、安慰剂对照试验中确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Poor outcomes have been reported in patients with type 2 diabetes and coronavirus disease 2019 (COVID-19); thus, it is mandatory to explore novel therapeutic approaches for this population. RESEARCH DESIGN AND METHODS: In a multicenter, case-control, retrospective, observational study, sitagliptin, an oral and highly selective dipeptidyl peptidase 4 inhibitor, was added to standard of care (e.g., insulin administration) at the time of hospitalization in patients with type 2 diabetes who were hospitalized with COVID-19. Every center also recruited at a 1:1 ratio untreated control subjects matched for age and sex. All patients had pneumonia and exhibited oxygen saturation <95% when breathing ambient air or when receiving oxygen support. The primary end points were discharge from the hospital/death and improvement of clinical outcomes, defined as an increase in at least two points on a seven-category modified ordinal scale. Data were collected retrospectively from patients receiving sitagliptin from 1 March through 30 April 2020. RESULTS: Of the 338 consecutive patients with type 2 diabetes and COVID-19 admitted in Northern Italy hospitals included in this study, 169 were on sitagliptin, while 169 were on standard of care. Treatment with sitagliptin at the time of hospitalization was associated with reduced mortality (18% vs. 37% of deceased patients; hazard ratio 0.44 [95% CI 0.29-0.66]; P = 0.0001), with an improvement in clinical outcomes (60% vs. 38% of improved patients; P = 0.0001) and with a greater number of hospital discharges (120 vs. 89 of discharged patients; P = 0.0008) compared with patients receiving standard of care, respectively. CONCLUSIONS: In this multicenter, case-control, retrospective, observational study of patients with type 2 diabetes admitted to the hospital for COVID-19, sitagliptin treatment at the time of hospitalization was associated with reduced mortality and improved clinical outcomes as compared with standard-of-care treatment. The effects of sitagliptin in patients with type 2 diabetes and COVID-19 should be confirmed in an ongoing randomized, placebo-controlled trial.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Solerte SB, D'Addio F, Trevisan R, et al. Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study. Diabetes Care. 2020. PMID: 32994187. doi:10.2337/dc20-1521

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。